Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OCUL
Strong SellHot AirOcular Therapeutix, Inc. · Healthcare · United States · $2.3B · Avg Vol: $28M/d
COMPANY DESCRIPTION
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company's competitive moat is anchored by its proprietary bioresorbable hydrogel platform, which enables sustained-release drug delivery and eliminates the need for daily eye drops. It operates as a leading ophthalmic innovator with a commercialized product portfolio and a high-potential clinical pipeline targeting wet AMD.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.5M | 58.4M | 63.7M | 52.0M | 0.3% | 52.1M | 52.9M | 102.5M | 40.4% |
| EPS | -0.32 | -1.01 | -1.22 | -1.42 | — | -1.40 | -1.43 | -1.45 | — |
| Shares | 219.0M | 115.0M | 157.7M | 215.9M | -1.4% | 219.6M | — | — | — |
| Debt | 64.3M | 83.4M | 75.8M | 77.0M | 6.2% | 79.4M | — | — | — |
| Equity | 35.4M | 91.1M | 315.3M | 654.3M | 164.5% | — | — | — | — |
| Op CF | -59.6M | -70.2M | -134.7M | -204.9M | — | -238.2M | — | — | — |
| Inv CF | -3.7M | -6.1M | -1.3M | -11.9M | — | — | — | — | — |
| Fin CF | 1.5M | 169.8M | 332.1M | 561.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OCUL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc.(you) | $2.3B | 18 | Strong Sell |
| BHVN | Biohaven Ltd. | $2.3B | 18 | Strong Sell |
| RAPP | Rapport Therapeutics, Inc. | $2.3B | 19 | Strong Sell |
| PVLA | Palvella Therapeutics, Inc. | $2.2B | 16 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| KOD | Kodiak Sciences Inc. | $2.4B | 12 | Strong Sell |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 20 | Sell |
| NKTR | Nektar Therapeutics | $2.5B | 23 | Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%